rheumatoid arthritis

Aclaris shares plummet on terminating development of rheumatoid arthritis drug
Aclaris shares plummet on terminating development of rheumatoid arthritis drug
Reuters
Aclaris
Therapeutics
rheumatoid arthritis
clinical trials
zunsemetinib
Flag link:
Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis
Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis
Biopharma Reporter
Janssen
JNJ
rheumatoid arthritis
nipocalimab
clinical trials
Flag link:
Here come the PD-1 agonists
Here come the PD-1 agonists
EP Vantage
PD-1 agonists
autoimmune disease
Eli Lilly
rheumatoid arthritis
peresolimab
Flag link:
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Drugs.com
Eli Lilly
peresolimab
rheumatoid arthritis
clinical trials
Flag link:
Gilead, EVOQ Unite on 'Potential Breakthrough' Treatment for RA, Lupus
Gilead, EVOQ Unite on 'Potential Breakthrough' Treatment for RA, Lupus
BioSpace
Gilead Sciences
Evoq Therapeutics
lupus
rheumatoid arthritis
Flag link:
GSK dumps major pipeline prospect otilimab on lackluster phase 3 data in rheumatoid arthritis
GSK dumps major pipeline prospect otilimab on lackluster phase 3 data in rheumatoid arthritis
Fierce Biotech
GSK
otilimab
rheumatoid arthritis
Flag link:
Big pharma’s key third-quarter data
Big pharma’s key third-quarter data
EP Vantage
GSK
Roche
Pfizer
JNJ
AstraZeneca
Novo Nordisk vaccines
clinical trials
pneumococcal disease
crovalimab
rheumatoid arthritis
Flag link:
J&J, BMS arthritis drugs lowered death risk among COVID patients in federal study
J&J, BMS arthritis drugs lowered death risk among COVID patients in federal study
Fierce Pharma
JNJ
Bristol Myers Squibb
COVID-19
rheumatoid arthritis
clinical trials
Orencia
Remicade
Flag link:
Biogen and Xbrane in deal on rheumatoid arthritis targeting biosimilar
Biogen and Xbrane in deal on rheumatoid arthritis targeting biosimilar
Biopharma Reporter
Biogen
Xbrane Biopharma
monoclonal antibodies
Xcimzane
Cimzia
rheumatoid arthritis
Flag link:
Galvani Bioelectronics implants first neurostimulator for splenic nerve stimulation in rheumatoid arthritis patient
Galvani Bioelectronics implants first neurostimulator for splenic nerve stimulation in rheumatoid arthritis patient
MedCity News
GSK
Verily
Galvani Bioelectronics
neurostimulation
rheumatoid arthritis
splenic nerve stimulation
Flag link:
Scipher Medicine’s blood test shows the benefits of precision medicine in rheumatoid arthritis
Scipher Medicine’s blood test shows the benefits of precision medicine in rheumatoid arthritis
MedCity News
Scipher Medicine
precision medicine
PrismRA
rheumatoid arthritis
Medtech
diagnostics
Flag link:
A three-decade monopoly: How Amgen built a patent thicket around its top-selling drug
A three-decade monopoly: How Amgen built a patent thicket around its top-selling drug
BioPharma Dive
Amgen
Enbrel
rheumatoid arthritis
patents
Flag link:
How Researchers Stumbled Upon an Arthritis Vaccine Just in Time for World Arthritis Day
How Researchers Stumbled Upon an Arthritis Vaccine Just in Time for World Arthritis Day
Xtalks
vaccines
rheumatoid arthritis
Flag link:
Galapagos avoids 'complete whiff' as key anti-inflammatory drug fails to beat placebo in midphase trials
Galapagos avoids 'complete whiff' as key anti-inflammatory drug fails to beat placebo in midphase trials
Fierce Biotech
Galapagos
clinical trials
rheumatoid arthritis
ulcerative colitis
psoriasis
filgotinib
Flag link:
Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial
Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial
Yahoo/Benzinga
Eli Lilly
clinical trials
rheumatoid arthritis
olumiant
Flag link:
AbbVie's Rinvoq rollout on track despite JAK safety concerns, but uncertainty remains: analyst
AbbVie's Rinvoq rollout on track despite JAK safety concerns, but uncertainty remains: analyst
Fierce Pharma
AbbVie
Rinvoq
Xeljanz
FDA
rheumatoid arthritis
Flag link:
AbbVie's approval delay raises further concerns about JAK drugs
AbbVie's approval delay raises further concerns about JAK drugs
BioPharma Dive
AbbVie
FDA
Rinvoq
rheumatoid arthritis
Flag link:
FDA holds back from action over Xeljanz safety study FDA holds back from action over Xeljanz safety study
FDA holds back from action over Xeljanz safety study FDA holds back from action over Xeljanz safety study
Pharmaforum
Pfizer
FDA
Xeljanz
rheumatoid arthritis
Flag link:
Pfizer bags rheumatoid arthritis rights to new immunotherapy class through deal with Imcyse
Pfizer bags rheumatoid arthritis rights to new immunotherapy class through deal with Imcyse
Fierce Biotech
Pfizer
Imcyse
rheumatoid arthritis
drug development
Flag link:
Aclaris MK2 bears fruit
Aclaris MK2 bears fruit
EP Vantage
Aclaris
rheumatoid arthritis
clinical trials
ATI-450
Flag link:

Pages